Menu
Founder And President
Co-Founding Partner and COO
Chief Financial Officer
Chief People Officer
Partner, Launch Excellence Practice Lead
Partner, Patient Services Practice Lead
Partner, Market Access Practice Lead
General Manager, SixSense Strategy Group, Medical Affairs Practice Lead
Principal, Medical Communications
Principal, Evidence and Value
Principal, Science and Strategy
Principal, Evidence and Value
Principal, Market Access
Principal, Market Access
Principal
Principal
Principal, Scientific Communications
Principal, Science and Strategy
Senior Director, Market Access
Senior Vice President, Commercialization
Vice President, Commercialization
Director, Market Access
Senior Vice President, Commercialization
Director, Patient Services
Vice President, Business Development
Executive Vice President, Business Development
Senior Vice President, Commercialization
Beth Schurman is a Partner at Herspiegel and an experienced marketing professional with extensive experience in the pharmaceutical industry. Beth has a broad marketing background, including experience in brand development, new product launches, market shaping, and life cycle management. Her strong leadership, attention to detail, and communication skills have earned her the trust and respect of her clients.
Beth expertly blends marketing strategy, innovative thinking, and rigorous structure to establish market-changing strategies and impactful execution for her clients. Clients value her ability to smoothly transition from strategy development and innovation to project management and analytics. Beth has led a variety of projects spanning therapeutic areas, including oncology, rare disease, diabetes, obesity, infectious disease, CNS and trauma.
Prior to her tenure with Herspiegel, Beth gained extensive marketing experience at both Novo Nordisk and Bristol-Meyers Squibb. She was highly involved in product launch, co-promotions, and in-line brand management in retail and hospital markets.
Beth has an MBA with specializations in Marketing and Management from the Stern School of Business at NYU, and a BA in Biochemistry and Molecular Biology from Rutgers University.
